Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics and biotechnology company whose news flow centers on the development of Klotho gene-based cell and gene therapies for neurodegenerative and age-related disorders. Company announcements describe programs built around a protein derived from a patented form of the human “anti-aging” Klotho gene (s-KL), with a focus on conditions such as ALS, Alzheimer’s disease, and Parkinson’s disease, as well as broader longevity-related indications.
News items for KLTO commonly cover pipeline progress, including manufacturing and development updates for gene therapy candidates like KLTO-101 and KLTO-202, and regulatory milestones such as Orphan Drug Designation for KLTO-202 for the treatment of ALS. Releases also highlight strategic partnerships, notably Klotho’s collaboration with AAVnerGene Inc. to use AAVone and ATHENA platforms for AAV-based manufacturing and tissue-targeted delivery of Klotho gene therapies.
Investors following KLTO news will also see corporate and financing developments, including capital raises, preferred stock transactions described in the company’s S-1 registration statement, and Nasdaq listing and compliance updates. Strategic updates outline Klotho’s efforts to expand beyond neurology into technologies that support healthy brain function, organ health, muscle strength, bone health, and other longevity indicators, as well as its evaluation of complementary longevity-related assets.
Coverage further includes conference participation and scientific engagement, such as presentations at biotech and longevity-focused events and the Inaugural Klotho Conference & Scientific Seminar, where advisors and inventors discuss Klotho gene therapy research. For readers interested in KLTO, this news page aggregates these disclosures so they can review pipeline milestones, partnership announcements, regulatory updates, and strategic communications in one place.
Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, will present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PT at the Hilton San Francisco Union Square.
CEO Dr. Joseph Sinkule will discuss the company's work with the secreted form of the Klotho anti-aging gene ('s-KL'), their patent-protected development platform. The company aims to increase awareness of this 'master gene' and its potential role in treating neurodegenerative diseases. They are progressing toward clinical trials for ALS and seeking development partnerships for Alzheimer's and Parkinson's treatments.
KLTO has secured exclusive worldwide licenses from UAB and ICREA in Spain, with patents issued in the USA, Europe, and China for their therapeutic approach using s-KL to treat cognitive and behavioral impairments.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board. Dr. Cudkowicz is the Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and Julieanne Dorn Professor of Neurology at Harvard Medical School. She is a member of the National Academy of Medicine and co-director of the Northeast ALS Consortium, overseeing 150+ clinical sites in the US and Canada.
The company, focused on developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, aims to leverage Dr. Cudkowicz's expertise in clinical trial design and execution. Their approach centers on a patent-protected product candidate expressing the Klotho gene transcribed protein called 's-KL' or 'secreted Klotho' for ALS treatment.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. During his tenure at Merck, El-Dada managed over $12 billion in revenue across multiple therapeutic areas and served as Managing Director for Australia and New Zealand operations. His experience includes product development, commercialization, strategic partnerships, and policy engagement through the Healthcare Leadership Council. The appointment aims to strengthen the company's development of S-KL, a patent-protected Klotho gene therapy targeting ALS, Alzheimer's, and Parkinson's diseases.
Klotho Neurosciences (NASDAQ: KLTO) announces the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o is renowned for discovering the Klotho gene, known as the 'anti-aging gene,' during his research at the National Institute of Neuroscience in Tokyo. His research showed that mice lacking the Klotho gene aged faster, while those overexpressing it lived longer. The company is developing a patent-protected secreted form of Klotho (s-KL) for treating neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's disease.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its new Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership team and accelerate the development of its therapeutic candidates. Moriarty brings extensive experience in the pharmaceutical industry, including leadership roles at multinational companies and entrepreneurial success.
Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, highlighted Moriarty's expertise in operational management, strategic execution, and corporate culture development. Moriarty expressed enthusiasm for joining KLTO, citing its robust portfolio and promising cell and gene therapy platform. The company's focus is on developing breakthrough treatments for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, leveraging its exclusive worldwide license from the Autonomous University of Barcelona for treatments based on the secreted form of the Klotho gene (s-KL).
Klotho Neurosciences (NASDAQ: KLTO) has announced that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. Dr. Langer, a renowned biotech leader and MIT professor, will contribute his expertise in neuroscience and therapeutics development. Klotho Neurosciences is developing novel therapies for neurodegenerative diseases, leveraging research on the Klotho protein, an anti-aging factor with neuroprotective potential.
The company's platform focuses on the secreted form of Klotho, s-KL, which is patented in several countries. Dr. Joseph Sinkule, Chairman and CEO of Klotho Neurosciences, expressed enthusiasm about Dr. Langer's vast experience in translational medicine and therapeutic innovation. Dr. Langer will provide guidance on the scientific and clinical development of the company's product candidates, supporting efforts to address major unmet medical needs in neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease.